Disclosed herein are methods and compounds for treating augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, also disclosed herein include methods of activating and enhancing the cGAS-STING response and use of an inhibitor of a phosphodiesterase for the treatment of a microbial infection.
